# Lokavant

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lokavant

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.lokavant.com
- Total disclosed funding: $29M
- Latest round: Series A (Oct 3, 2023)
- Investors on record: 3

## About

Based in New York, US, and founded in 2020, Lokavant, Inc., operates as a clinical intelligence company that improves the time, cost, and quality of trial execution through its data-driven analytics platform. Lokavant, Inc., operates as a clinical intelligence company that improves the time, cost, and quality of trial execution through its data-driven analytics platform. As of 2023, the company is led by its CEO, Rohit Nambisan, and partnered with companies like Halloran, CMIC, Parexel, Perficient, and many more.  In September 2025, ProofPilot, Inc., acquired Lokavant, Inc. to integrates predictive analytics with trial execution, expanding market reach, improving operational efficiency, and delivering a unified platform for sponsors and CROs to accelerate clinical research and mitigate risks

Lokavant, Inc. offers a clinical trial intelligence platform that provides real-time integration and harmonization of all clinical trial data for study planning and operations. The company also provides forecasting, risk detection, medical monitoring, automated reporting, a real-time view of TMF completeness to ensure audit readiness, and data and insights enabling study planning and oversight for clinical trials. 

The acquisition integrates Lokavant’s predictive analytics with ProofPilot’s trial execution platform, enhancing efficiency and accelerating clinical research.

## Funding rounds

- Series A, Oct 3, 2023, $8M — Mitsui Global Investment
- Series A, Dec 7, 2022, $21M — Edison Partners, Roivant Sciences Ltd.

## Investors

- Edison Partners (https://capitalatlas.ai/funds/edison-partners) — Series A
- Roivant Sciences Ltd. — Series A
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series A